Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
暂无分享,去创建一个
J. Mascola | Reda Rawi | Baoshan Zhang | N. Doria-Rose | M. Louder | K. Mckee | L. Shapiro | P. Kwong | Yongping Yang | J. Gorman | E. Yang | M. Asokan | Tatsiana Bylund | A. Pegu | Shuishu Wang | A. Schön | Y. Kwon | A. Olia | M. Seaman | C. W. Chao | Kevin Carlton | Cuiping Liu | Deepika Gollapudi | Tracy Liu | Michael F. Bender | P. Lei | Leland F. Damron | Yile Li | Baoshan Zhang
[1] J. Mascola,et al. Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life , 2022, Scientific Reports.
[2] Bradford W Tippett,et al. Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency , 2022, Scientific Reports.
[3] R. Weiss,et al. Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. , 2022, Structure.
[4] S. Zolla-Pazner,et al. Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces , 2021, Nature Communications.
[5] M. Farzan,et al. In vitro affinity maturation of broader and more-potent variants of the HIV-1–neutralizing antibody CAP256-VRC26.25 , 2021, Proceedings of the National Academy of Sciences.
[6] Baoshan Zhang,et al. A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. , 2021, Vaccine.
[7] Allan C. deCamp,et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. , 2021, The New England journal of medicine.
[8] J. Mascola,et al. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial , 2020, BMJ Open.
[9] G. Chuang,et al. Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains. , 2020, Cell reports.
[10] Conrad C. Huang,et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers , 2020, Protein science : a publication of the Protein Society.
[11] J. Mascola,et al. Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. , 2020, Cell reports.
[12] M. Farzan,et al. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies , 2020, mBio.
[13] R. Read,et al. Improvement of cryo-EM maps by density modification , 2019, Nature Methods.
[14] J. Mascola,et al. Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. , 2019, Structure.
[15] Mario Roederer,et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques , 2017, Science.
[16] B. Korber,et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge , 2017, Science Translational Medicine.
[17] D. Burton,et al. A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure , 2017, Immunity.
[18] David J. Fleet,et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.
[19] C. Soto,et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody , 2016, Science.
[20] Lynn Morris,et al. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection , 2016, PLoS pathogens.
[21] Lynn Morris,et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency , 2015, Journal of Virology.
[22] Young Do Kwon,et al. Crystal structure , conformational fixation , and entry-related interactions of mature ligand-free HIV-1 Env , 2016 .
[23] Nathaniel Echols,et al. EMRinger: Side-chain-directed model and map validation for 3D Electron Cryomicroscopy , 2015, Nature Methods.
[24] Thomas Emrich,et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics , 2014, Proceedings of the National Academy of Sciences.
[25] John P. Moore,et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.
[26] Tongqing Zhou,et al. Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.
[27] Young Do Kwon,et al. Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.
[28] Hongmei Gao,et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. , 2014, Journal of immunological methods.
[29] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[30] Tongqing Zhou,et al. Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization , 2013, Science.
[31] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[32] R. Weiss,et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization , 2012, The Journal of experimental medicine.
[33] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.
[34] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[35] Mario Roederer,et al. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.
[36] Kiran Mukhyala,et al. Effects of charge on antibody tissue distribution and pharmacokinetics. , 2010, Bioconjugate chemistry.
[37] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[38] T. Igawa,et al. Reduced elimination of IgG antibodies by engineering the variable region. , 2010, Protein engineering, design & selection : PEDS.
[39] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[40] Anchi Cheng,et al. Automated molecular microscopy: the new Leginon system. , 2005, Journal of structural biology.
[41] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[42] David C. Richardson,et al. MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes , 2004, Nucleic Acids Res..
[43] Randy J Read,et al. Recent developments in the PHENIX software for automated crystallographic structure determination. , 2004, Journal of synchrotron radiation.